AdvanCell Expands Strategic Collaboration with Eli Lilly for Targeted Alpha Therapies

• AdvanCell has expanded its strategic collaboration with Eli Lilly and Company to advance targeted alpha therapies for cancer treatment.

• The partnership will integrate AdvanCell’s Pb-212 production technology with Lilly’s oncology expertise to accelerate clinical development.

AdvanCell, a clinical-stage radiopharmaceutical company specialising in targeted alpha therapies, has announced an expansion of its collaboration with Eli Lilly and Company to advance innovative cancer treatments. The strengthened partnership will integrate AdvanCell’s proprietary Pb-212 production technology and radionuclide infrastructure with Lilly’s expertise in drug development.

The agreement aims to accelerate the clinical advancement of an expanded portfolio of targeted alpha therapies. AdvanCell’s infrastructure and early-stage clinical trial capabilities in Australia provide a competitive edge, facilitating the rapid development of Pb-212-based radiotherapeutics.

“This collaboration with Lilly represents a significant milestone for AdvanCell, recognizing our company as one of the leaders in the Pb-212 targeted alpha therapy space,” said Andrew Adamovich, CEO of AdvanCell. “By combining our groundbreaking isotope production capabilities, our team’s expertise and infrastructure with Lilly’s pharmaceutical and oncology expertise and global scale, we aim to bring transformative treatments to patients with hard-to-treat cancers.”

Jacob Van Naarden, President of Lilly Oncology, reinforced the importance of the partnership, stating, “Partnering with AdvanCell aligns with our commitment to advancing innovative radiopharmaceuticals. We are excited to explore the potential of Pb-212-based alpha therapies as we work to bring meaningful new treatments for patients.”